Finanzen von Kailera Therapeutics Inc (KLRA)KLRAKailera Therapeutics Inc

In the context of the broader market, KLRA competes directly with industry leaders such as COAG and ADMA. With a market capitalization of $2.13B, it holds a leading position in the sector. When comparing efficiency, KLRA's gross margin of N/A stands against COAG's N/A and ADMA's 69.31%. Such benchmarking helps identify whether Kailera Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Kailera has reported significant net losses, with Q2 2026 showing a net income loss of $111.3 million and an EPS of -1.09, indicating ongoing financial struggles.